05). When compared to the RAT and RAP, only the results of endoscopy, which is statistically significant (P < 0.05) which was RAT better than RAP. Conclusion: The use of a combination of teprenone, ranitidine, and antacids provided improved clinical, endoscopy, histopathology, inflammatory cells better than the combination of ranitidine, antacids and placebo in chronic gastritis. Key Word(s): 1. chronic gastritis; 2. teprenone; 3. endoscopic; 4. histopathology; Presenting Author:
IMAM SUPRIANTO Additional Authors: CT99021 datasheet SUYATA., SYADRA BARDIMAN, FUAD BAKRY Corresponding Author: IMAM SUPRIANTO Affiliations: Moehammad Hoesin hospital Objective: Chronic gastritis is a localized or diffuse chronic inflammation of the lining of the stomach, histopathologically characterized by infiltration of lymphocytes and plasma cells in the mucosa. The imbalance between aggressive and defensive factors leads to this condition. Teprenone is a systemic Tyrosine Kinase Inhibitor Library mouse cytoprotective agent used to repair gastric mucosal
lesions by increasing the synthesis, secretion, and mucus viscosity, increasing the gastric phospholipids, prostaglandin E2, prostacyclin and heat shock protein. The purpose of this study was to determine the effectiveness of teprenone as an adjunct in the treatment of chronic gastritis Methods: This study was a double blind randomized clinical trial in the form of add on, which conducted at the outpatient clinic of Gastroenterology and Hepatology, Department of Internal Medicine Moehammad Hoesin Hospital Palembang, from June 2011 until February 2012. Patients were divided into 2 groups: the group given ranitidine, antacids, placebo (RAP) and the group given ranitidine, antacids, teprenone (RAT) for 4 weeks. Effectiveness assessed by clinical improvement, endoscopy, histopathology, inflammatory cells and Helicobacter Pylori. Data were analyzed using SPSS version 17 with the X2 and T test. Results: Of
the 40 patients who participated in this study, 12 men and 28 women, there were statistically significant differences in the RAT groups in the improvement of clinical symptoms, endoscopy, histopathology, 上海皓元 inflammatory cells and Helicobacter Pylori (P < 0.05). While in the RAP group, there was no significant difference in improvement of endoscopy, histopathology, inflammatory cells and Helicobacter Pylori (P > 0.05). When compared to the RAT and RAP, only the results of endoscopy, which is statistically significant (P < 0.05) which was RAT better than RAP. Conclusion: The use of a combination of teprenone, ranitidine, and antacids provided improved clinical, endoscopy, histopathology, inflammatory cells better than the combination of ranitidine, antacids and placebo in chronic gastritis. Key Word(s): 1. chronic gastritis; 2. teprenone; 3. endoscopic; 4.